Okay, here’s a revised and fact-checked version of the provided text, incorporating corrections and updates based on current understanding of Alzheimer’s Disease (AD). I’ve included explanations of the changes made at the end.
—
## Alzheimer’s Disease: A Multifactorial Approach to Diagnosis and Treatment
The speaker explained that a predisposition to develop alzheimer’s Disease (AD) is influenced by multiple factors. Genetic factors play a role,particularly in conditions like Down syndrome,which considerably increases risk. Early life experiences, including the quality of education and cognitive stimulation, are also crucial, as robust brain development can contribute to cognitive reserve and potentially delay the onset of symptoms.
Diagnosis of AD requires evidence of three key pathological hallmarks: the presence of amyloid plaques, tau tangles, and neuronal damage. These are assessed thru neuroimaging techniques, such as magnetic resonance imaging (MRI) and positron emission tomography (PET) scans, as well as through the analysis of biomarkers in cerebrospinal fluid (CSF) and blood (plasma).
The expert highlighted variations in biomarker utilization globally, noting that not all laboratories have access to the necessary resources for comprehensive testing. The need for highly sensitive and specific biomarkers is particularly critical in the early, pre-symptomatic stages of the disease.
Dr. Chiquete Anaya emphasized the following key points: “AD is a multifactorial disease in the vast majority of patients